Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699656 · ClinicalTrials.gov registry record · Phase 1
Plazomicin Study in ESRD Patients Receiving IHD
A Phase 1 study of End Stage Renal Disease, sponsored by Cipla USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT04699656 is a Phase 1 study of End Stage Renal Disease that has completed, run by Cipla USA. The registered enrollment target is 6 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04699656, a Phase 1 study of End Stage Renal Disease, has completed, sponsored by Cipla USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to directly characterize the pharmacokinetic (PK) profile of plazomicin following administration of a single oral dose before and after IHD in subjects with ESRD. This PK assessment will be used to provide appropriate plazomicin dosing recommendations for patients with ESRD receiving IHD.
Conditions Studied
Interventions
- DRUG Plazomicin Injection
Study Locations (1)
Florida
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2021-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04699656
The ClinicalTrials.gov registry entry for NCT04699656 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The listed sponsor is Cipla USA, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Plazomicin Injection is the first listed.
NCT04699656 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04699656 about?
NCT04699656 is a clinical study titled "Plazomicin Study in ESRD Patients Receiving IHD". This study is being conducted to directly characterize the pharmacokinetic (PK) profile of plazomicin following administration of a single oral dose before and after IHD in subjects with ESRD. This PK assessment will be used to provide appropriate plazomicin dosing recommendations for patients with ...
What is the current status of trial NCT04699656?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-01-05. Estimated completion is 2021-06-09.
What conditions does trial NCT04699656 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT04699656?
The interventions under investigation include: Plazomicin Injection (DRUG).
Who is sponsoring clinical trial NCT04699656?
This trial is sponsored by Cipla USA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04699656 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.